|Table of Contents|

The efficacy and toxicity of induction chemotherapy with cisplatin and capcitabine for locally advanced nasopharyngeal carcinoma

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2018 04
Page:
516-519
Research Field:
Publishing date:

Info

Title:
The efficacy and toxicity of induction chemotherapy with cisplatin and capcitabine for locally advanced nasopharyngeal carcinoma
Author(s):
Yang Li; Xu Zhiyuan; Li Jishi; Chen Zhijian
Clinical Oncology Center，the University of Hong Kong-Shenzhen Hospital,Guangdong Shenzhen 518053,China.
Keywords:
nasopharyngeal carcinoma; induction chemotherapy; capecitabine
PACS:
R739.6
DOI:
10.3969/j.issn.1672-4992.2018.04.008
Abstract:
Objective:Induction chemotherapy（IC) plus concurrent chemoradiotherapy（CCRT) could significantly reduce the hazard of progression and distant metastasis in locally advanced nasopharyngeal carcinoma（LA-NPC).However,no standard IC regimen is currently available.This study aims to prospectively evaluate the efficacy and toxicity of IC with cisplatin and capcitabine in the treatment of LA-NPC.Methods:From January 2015 to December 2016,fifty-six patients with LA-NPC were enrolled.All patients received 3 cycles of induction PX（cisplatin 80 mg/m2，day 1.Oral capecitabine 1 000 mg/m2,twice daily from day 1~14,repeated every 3 weeks).The following radiotherapy was determined by radiation oncologists.Tumor response was evaluated after 3 cycles of PX according to the World Health Organization（WHO) criteria.Toxicities were gauged based on the Common Terminology Criteria for Adverse Events version 4.03（CTCAE 4.03).Results:All patients received 3 cycles of induction PX.The objective response rate（ORR) after 3 cycles of PX at the primary site and the neck region were 78.6% ［complete response（CR) was 19.6%］ and 81.5%（CR was 7.4%) respectively.The combined ORR of the primary site and the neck region was 85.7%（CR was 3.6%).The incidence of grade 3-4 leukopenia/neutropenia,anemia,nausea/vomiting and electrolyte disturbance during PX were 14.3%,7.1%,5.4% and 17.9%,respectively.No grade 3-4 hand-foot syndrome,diarrhea or renal impairment was observed.There were no treatment-related deaths.Conclusion:Induction PX is highly effective and well tolerated in LA-NPC and warrant further investigation.

References:

[1]Chen W,Zheng R,Baade PD，et al.Cancer statistics in China,2015［J］.CA Cancer J Clin,2016,66:115-132.
[2]Mesic JB,Fletcher GH,Goepfert H.Megavoltage irradiation of epithelial tumors of the nasopharynx［J］.Int J Radiat Oncol Biol Phys,1981,7:447-453.
[3]Hoppe RT,Goffinet DR,Bagshaw MA.Carcinoma of the nasopharynx.Eighteen years' experience with megavoltage radiation therapy［J］.Cancer,1976,37:2605-2612.
[4]Pfister DG,Spencer S,Brizel DM，et al.Head and Neck Cancers,Version 1.2015［J］.J Natl Compr Canc Netw, 2015,13:847-855.
[5]Lee AW,Tung SY,Ngan RK，et al.Factors contributing to the efficacy of concurrent-adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma:Combined analyses of NPC-9901 and NPC-9902 trials［J］.Eur J Cancer,2011,47:656-666.
[6]Lee AW,Lau KY,Hung WM,et al.Potential improvement of tumor control probability by induction chemotherapy for advanced nasopharyngeal carcinoma［J］.Radiotherapy & Oncology,2008,87:204-210.
[7]Song Y,Wang W,Tao G,et al.Survival benefit of induction chemotherapy in treatment for locally advanced nasopharyngeal carcinoma—A time-to-event Meta-analysis［J］.Oral Oncol,2015,51:764-769.
[8]Chan AT,Gregoire V,Lefebvre JL,et al.Nasopharyngeal cancer:EHNS-ESMO-ESTRO clinical practice guidelines for diagnosis,treatment and follow-up［J］.Ann Oncol,2012,23(Suppl 7):vii83-85.
[9]Lee AW,Ngan RK,Tung SY,et al.Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy,changing from fluorouracil to capecitabine,and changing from conventional to accelerated radiotherapy fractionation in patients with locoregionally advanced nasopharyngeal carcinoma［J］.Cancer,2015,121:1328-1338.
[10]Miller AB,Hoogstraten B,Staquet M,et al.Reporting results of cancer treatment［J］.Cancer,1981,47:207-214.
[11]National Cancer Institute,National Institutes of Health,US Department of Health and Human Services.Common Terminology Criteria for Adverse Events（CTCAE) Version 4.0［S/OL］.NIH publication # 09-7473,2009-05-29［Revised Version 4.03 2010-06-14］.http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5×7.pdf.
[12]Baujat B,Audry H,Bourhis J,et al.Chemotherapy in locally advanced nasopharyngeal carcinoma:An individual patient data Meta-analysis of eight randomized trials and 1753 patients［J］.Int J Radiation Oncol Biol Phys,2006,64:47.
[13]Al-Amro A,Al-Rajhi N,Khafaga Y,et al.Neoadjuvant chemotherapy followed by concurrent chemo-radiation therapy in locally advanced nasopharyngeal carcinoma［J］.Int J Radiat Oncol Biol Phys,2005,62:508-513.
[14]Bae WK,Hwang JE,Shim HJ,et al.Phase Ⅱ study of docetaxel,cisplatin,and 5-FU induction chemotherapy followed by chemoradiotherapy in locoregionally advanced nasopharyngeal cancer［J］.Cancer Chemother Pharmacol,2010,65:589-595.
[15]Hui EP,Ma BB,Leung SF,et al.Randomized phase Ⅱ trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma［J］.J Clin Oncol,2009,27:242-249.
[16]Saif MW,Eloubeidi MA,Russo S,et al.Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer:Expression analysis of genes related to outcome［J］.J Clin Oncol,2005,23:8679-8687.
[17]Walko CM,Lindley C.Capecitabine:A review［J］.Clin Ther,2005,27:23-44.
[18]Hoff PM,Ansari R,Batist G,et al.Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer:Results of a randomized phase Ⅲ study［J］.J Clin Oncol,2001,19:2282-2292.
[19]Van Cutsem E,Twelves C,Cassidy J,et al.Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer:Results of a large phase Ⅲ study［J］.J Clin Oncol,2001,19:4097-4106.
[20]Cassidy J,Saltz L,Twelves C,et al.Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers:A Meta-analysis of individual data from 6171 patients［J］.Ann Oncol,2011,22:2604-2609.
[21]Wang Y,Yang H,Wei JF,et al.Efficacy and toxicity of capecitabine-based chemotherapy in patients with metastatic or advanced breast cancer:Results from ten randomized trials［J］.Curr Med Res Opin,2012,28:1911-1919.
[22]Chua DT,Sham JS,Au GK.A phase Ⅱ study of capecitabine in patients with recurrent and metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy［J］.Oral Oncol,2003,39:361-366.
[23]Blachley JD,Hill JB.Renal and electrolyte disturbances associated with cisplatin［J］.Ann Intern Med,1981,95:628-632.
[24]Tsavaris N,Charalambidis G,Ganas N,et al.Ondansetron versus metoclopramide as antiemetic treatment during cisplatin-based chemotherapy.A prospective study with special regard to regard to electrolyte imbalance［J］.Acta Oncol,1995,34:243-246.
[25]Bearcroft CP,Domizio P,Mourad FH,et al.Cisplatin impairs fluid and electrolyte absorption in rat small intestine:A role for 5-hydroxytryptamine［J］.Gut,1999,44:174-179.

Memo

Memo:
-
Last Update: 2017-12-29